Tamarack Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Tamarack Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-400,000	Closed	-$24.9M	–	41
2015 Q1	$24.9M	Buy	400,000 +15,000	+4%	+$872K	3.28%	10
2014 Q4	$22.1M	Buy	385,000 +155,000	+67%	+$8.64M	3.36%	9
2014 Q3	$12.4M	Sell	230,000 -16,500	-7%	-$874K	2.74%	13
2014 Q2	$13.3M	Buy	+246,500	New	+$12.6M	2.71%	11

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Tamarack Capital Management's TEVA Position: Q2 2015 in Review

Tamarack Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 400,000 shares — an estimated $24.9M sold.

Tamarack Capital Management first reported a position in TEVA in Q2 2014 and held it in 4 quarters. The position peaked at $24.9M in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Tamarack Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Tamarack Capital Management sold 400,000 Teva Pharmaceuticals shares in Q2 2015, an estimated $24.9M.
Tamarack Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Tamarack Capital Management's Teva Pharmaceuticals position peaked at $24.9M in Q1 2015.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Tamarack Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.